Gerard J Marek

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders
    Gerard J Marek
    Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA
    Neuropsychopharmacology 28:402-12. 2003
  2. ncbi request reprint Behavioral evidence for mu-opioid and 5-HT2A receptor interactions
    Gerard J Marek
    Department of Psychiatry, Yale School of Medicine, New Haven, CT 06508, USA
    Eur J Pharmacol 474:77-83. 2003
  3. ncbi request reprint AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes
    Ce Zhang
    Department of Psychiatry, Yale University School of Medicine, Ribicoff Research Facilities of the Connecticut Mental Health Center, New Haven, Connecticut, USA
    Prog Neuropsychopharmacol Biol Psychiatry 32:62-71. 2008
  4. ncbi request reprint Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study
    Yili Shang
    Global Research and Development, Pfizer Inc, Groton, CT 06340, USA
    J Clin Psychopharmacol 27:71-5. 2007
  5. ncbi request reprint Group III metabotropic glutamate receptor agonists selectively suppress excitatory synaptic currents in the rat prefrontal cortex induced by 5-hydroxytryptamine2A receptor activation
    Ce Zhang
    Department of Psychiatry, Yale University School of Medicine, Ribicoff Research Facilities of the Connecticut Mental Health Center, New Haven, Connecticut, USA
    J Pharmacol Exp Ther 320:437-47. 2007
  6. ncbi request reprint 5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740
    Gerard J Marek
    Yale School of Medicine, Department of Psychiatry, New Haven, CT 06508, USA
    Neurosci Lett 403:256-60. 2006
  7. ncbi request reprint The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine
    Gerard J Marek
    Department of Psychiatry, Yale School of Medicine, Connecticut Mental Health Center and the Ribicoff Research Facilities, New Haven, CT, USA
    Neuropsychopharmacology 30:2205-15. 2005
  8. ncbi request reprint Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors
    Jonathan C Gewirtz
    Yale School of Medicine, Department of Psychiatry, Ribicoff Research Facilities of the Connecticut Mental Health Center, Room 335d, 34 Park Street, New Haven, CT 06508, USA
    Pharmacol Biochem Behav 73:317-26. 2002
  9. ncbi request reprint Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid
    Linda M Rorick-Kehn
    Neuroscience Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, DC0510, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 321:308-17. 2007
  10. ncbi request reprint Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule
    JAMES M O'DONNELL
    Department of Pharmacology, University of Tennessee Health Science Center, 874 Union Avenue, Memphis, TN 38163, USA
    Neurosci Biobehav Rev 29:785-98. 2005

Collaborators

  • Yili Shang
  • Linda M Rorick Kehn
  • F Artigas
  • J Seibyl
  • K Marek
  • Linda Carpenter
  • Ce Zhang
  • Linda M Rorick-Kehn
  • JAMES M O'DONNELL
  • Jonathan C Gewirtz
  • Marc F Herin
  • Darryle D Schoepp
  • Ann E Kingston
  • Jennifer L Burkey
  • Deborah D Giera
  • James A Monn
  • Bryan G Johnson
  • David O Calligaro
  • Rebecca A Wright
  • John T Catlow
  • David L McKinzie
  • Eric S Nisenbaum
  • Lewis S Seiden
  • Rose Terwilliger
  • Andrew C Chen
  • Ronald C Duman

Detail Information

Publications12

  1. ncbi request reprint Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders
    Gerard J Marek
    Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA
    Neuropsychopharmacology 28:402-12. 2003
    ....
  2. ncbi request reprint Behavioral evidence for mu-opioid and 5-HT2A receptor interactions
    Gerard J Marek
    Department of Psychiatry, Yale School of Medicine, New Haven, CT 06508, USA
    Eur J Pharmacol 474:77-83. 2003
    ..In contrast, a delta-opioid receptor agonist was without effect on DOI-induced head shakes. Thus, activation of mu-opioid receptors can suppress head shakes induced by hallucinogenic drugs...
  3. ncbi request reprint AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes
    Ce Zhang
    Department of Psychiatry, Yale University School of Medicine, Ribicoff Research Facilities of the Connecticut Mental Health Center, New Haven, Connecticut, USA
    Prog Neuropsychopharmacol Biol Psychiatry 32:62-71. 2008
    ..These findings expand the dependence of both channel blocking NMDA receptor antagonists and phenethylamine hallucinogens on enhancing extracellular glutamate...
  4. ncbi request reprint Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study
    Yili Shang
    Global Research and Development, Pfizer Inc, Groton, CT 06340, USA
    J Clin Psychopharmacol 27:71-5. 2007
    ....
  5. ncbi request reprint Group III metabotropic glutamate receptor agonists selectively suppress excitatory synaptic currents in the rat prefrontal cortex induced by 5-hydroxytryptamine2A receptor activation
    Ce Zhang
    Department of Psychiatry, Yale University School of Medicine, Ribicoff Research Facilities of the Connecticut Mental Health Center, New Haven, Connecticut, USA
    J Pharmacol Exp Ther 320:437-47. 2007
    ....
  6. ncbi request reprint 5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740
    Gerard J Marek
    Yale School of Medicine, Department of Psychiatry, New Haven, CT 06508, USA
    Neurosci Lett 403:256-60. 2006
    ....
  7. ncbi request reprint The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine
    Gerard J Marek
    Department of Psychiatry, Yale School of Medicine, Connecticut Mental Health Center and the Ribicoff Research Facilities, New Haven, CT, USA
    Neuropsychopharmacology 30:2205-15. 2005
    ..These results will be discussed in the context that the combined blockade of 5-HT(2A) receptors and serotonin transporters (SERT) may result in greater efficacy in treating neuropsychiatric syndromes than blocking either site alone...
  8. ncbi request reprint Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors
    Jonathan C Gewirtz
    Yale School of Medicine, Department of Psychiatry, Ribicoff Research Facilities of the Connecticut Mental Health Center, Room 335d, 34 Park Street, New Haven, CT 06508, USA
    Pharmacol Biochem Behav 73:317-26. 2002
    ..BDNF mRNA expression was not altered by administration of the mGlu agonist or the antagonist alone. These results are discussed with respect to a potential role for group II mGlu agonists in the treatment of depression and schizophrenia...
  9. ncbi request reprint Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid
    Linda M Rorick-Kehn
    Neuroscience Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, DC0510, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 321:308-17. 2007
    ..Collectively, the current data indicate that LY404039 may be valuable in the treatment of neuropsychiatric disorders, including anxiety and psychosis...
  10. ncbi request reprint Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule
    JAMES M O'DONNELL
    Department of Pharmacology, University of Tennessee Health Science Center, 874 Union Avenue, Memphis, TN 38163, USA
    Neurosci Biobehav Rev 29:785-98. 2005
    ..Finally, the results of studies using DRL behavior highlight important roles for central beta-1 adrenergic receptors, as well as 5-HT1A, 5-HT1B, 5-HT2A, and 5-HT2C receptors, in the mediation of antidepressant-like behavioral effects...
  11. ncbi request reprint Metabotropic glutamate 2/3 receptors as drug targets
    Gerard J Marek
    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Opin Pharmacol 4:18-22. 2004
    ....
  12. pmc Cortical 5-hydroxytryptamine2A-receptor mediated excitatory synaptic currents in the rat following repeated daily fluoxetine administration
    Gerard J Marek
    Discovery Biology, Eli Lilly and Company, Lilly Corporate Center, Mail Drop 0510, Indianapolis, IN 46285 USA
    Neurosci Lett 438:312-6. 2008
    ..These findings would be consistent with the hypothesis that blockade of 5-HT(2A) receptors may enhance the effects of SSRIs or serotonin/norepinephrine reuptake inhibitors (SNRIs)...